32 results
Thumbnail

D2.02 - Clinically Relevant Cross-Reactivity Between Artemisia vulgaris and Bee Pollen: A New Paradigm in Postprandial Exercise-Induced Anaphylaxis

Thumbnail

D2.04 - PREVALENCE OF ALPHA-GAL SENSITIZATION IN PATIENTS WITH ARTHROPOD BITE REACTIONS, CHRONIC SPONTANEOUS URTICARIA AND GASTROINTESTINAL SYMPTOMS IN LA RIOJA (SPAIN). Introduction

Thumbnail

D2.06 - Clinical Characteristics of Reactions to Oral Food Challenges with Egg- and Milk-Based Muffins in Children

Thumbnail

D2.07 - Cross-reactivity of Major Pollen Allergens in Spring in Beijing

Thumbnail

D2.08 - Extraction Efficiency Studies and Quantification of Major Peanut Allergens in Peanut Challenge Meals and Peanut Flour

Thumbnail

D2.09 - Qualitative concordance between two multiplex molecular diagnostic platforms in LTP allergy

Thumbnail

D2.10 - Early-onset cow’s milk protein and tree nut allergy: the value of component-resolved diagnosis in interpreting low-level alpha-gal sensitization

Thumbnail

D2.12 - Resolving heterophile antibody interference in the ISAC multiplex assay using HBT (Scantibodies)

Thumbnail

D2.13 - Migratory locust and house cricket as food allergy: cross reactivity or primary sensitivisation

Thumbnail

D2.14 - Component ratio analysis supports a targeted diagnostic approach in house dust mite allergy

Thumbnail

D2.03 - Cofactor-Dependent Anaphylaxis to Rosaceae and Citrus Fruits: Molecular Characterization Reveals High-Molecular-Weight Allergens Beyond Classical Panallergens

Thumbnail

D2.05 - Quail Egg Allergy with Independent Hen Egg Sensitization: Insights From Protein Profiling and Inhibition Assays

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project